CHEOP (Chop + Etoposide): the New Standard Regimen for Younger Patients with Low Risk (Low LDH) Aggressive Non-Hodgkin's Lymphoma (NHL)

Reviewer: Walter F. Sall, MD
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 10 de diciembre del 2001

Translation for this article does not exist


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

BEACOPP Regimen Effective for Initial Hodgkin's Treatment

Jul 21, 2011

BEACOPP regimen initially better than ABVD, but long-term outcomes similar

Low-Intensity Therapy Highly Effective in Burkitt's Lymphoma

Nov 15, 2013

High rates of freedom from disease, overall survival for standard-dose, lower-dose EPOCH-R treatment

Mitotane + Chemo Combo May Benefit Adrenocortical Cancer

May 3, 2012

Therapy has higher antitumor efficacy as first- and second-line therapy versus streptozocin-mitotane